GAVRETO®
100 mg, Hartkapseln
Zul.-Nr. 68'182

Public Risk Management Plan (RMP) Summary

Document Version 1.0
Document Date: 10.09.2021
Based on: Core-RMP Version 1.0

Roche Pharma (Schweiz) AG Gartenstrasse 9 CH-4052 Basel pharma.schweiz@roche.com www.roche.ch/pharma Tel. +41 61 715 41 11

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of "Gavreto" is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of "Gavreto" in Switzerland is the "Arzneimittelinformation/ Information sur le médicament" (see www.swissmedic.ch) approved and authorized by Swissmedic. "Roche Pharma (Schweiz) AG" is fully responsible for the accuracy and correctness of the content of the published summary RMP of Gavreto.

11. RISK-MINIMIZATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK-MINIMIZATION ACTIVITIES)

RISK-MINIMIZATION PLAN
11.1 ROUTINE RISK-MINIMIZATION MEASURES

Table 21 Description of Routine Risk Minimization Measures by Safety Concern

Safety concern	Routine risk-minimization activities
Important Identified Risks	
Pneumonitis	**Routine risk communication:** CDS section 2.2 – Dosage and Administration CDS section 2.4 – Warnings and Precautions CDS Section 2.6 – Undesirable Effects **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Sections 2.2 and 2.4 of the CDS "Interstitial Lung Disease/Pneumonitis" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Hypertension	**Routine risk communication:** CDS section 2.2 – Dosage and Administration CDS section 2.4 – Warnings and Precautions CDS Section 2.6 – Undesirable Effects **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Sections 2.2 and 2.4 of the CDS "Hypertension" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None

	Medicine's Legal Status Pralsetinib is a prescription only medicine
Hemorrhage	**Routine risk communication:** CDS section 2.2 – Dosage and Administration CDS section 2.4 – Warnings and Precautions CDS Section 2.6 – Undesirable Effects **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Sections 2.2 and 2.4 of the CDS "Hemorrhagic events" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Important Potential Risks	
Hepatotoxicity	**Routine risk communication:** CDS section 2.2 – Dosage and Administration CDS section 2.4 – Warnings and Precautions CDS Section 2.6 – Undesirable Effects **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Sections 2.2 and 2.4 of the CDS "Hepatic Transaminase Elevations" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Embryo-fetal Toxicity	**Routine risk communication:** CDS section 2.4 – Warnings and Precautions CDS section 2.5 – Use in Special Populations

	Routine risk-minimization activities recommending specific clinical measures to address the risk: Sections 2.4 and 2.5.1 of the CDS "Embryo-Fetal Toxicity" and "Females and Males of Reproductive Potential" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Tumor Lysis Syndrome	**Routine risk communication:** None **Routine risk-minimization activities recommending specific clinical measures to address the risk:** None **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Severe Infections	**Routine risk communication:** None **Routine risk-minimization activities recommending specific clinical measures to address the risk:** None **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Physeal Dysplasia	**Routine risk communication:** CDS Section 2.5 – Use in special population

	CDS Section 3.2.5 - Pharmacokinetics in Special Populations **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Section 2.5.4 of the CDS "Use in special population" provides recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Missing Information	
Use in Patients with Severe Hepatic Impairment	**Routine risk communication:** CDS Section 2.2.1 – Special Dosage Instructions CDS Section 2.5.7 – Hepatic Impairment CDS Section 3.2.5 – Pharmacokinetics in Special Populations **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Not applicable **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Use in Children	**Routine risk communication:** CDS Section 2.2.1 – Special Dosage Instructions CDS Section 2.5.4 – Pediatric Use CDS Section 3.2.5 – Pharmacokinetics in Special Populations **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Not applicable **Other risk minimization measures beyond the Product Information:**

	None **Medicine's Legal Status** Pralsetinib is a prescription only medicine
Drug-drug Interaction	**Routine risk communication:** CDS Section 2.2 – Dosage and Administration CDS Section 2.8 – Interactions with other Medicinal Products and Other Forms of Interactions CDS Section 3.2.3 – Metabolism **Routine risk-minimization activities recommending specific clinical measures to address the risk:** Sections 2.2 and 2.8 of the CDS "Interactions with other Medicinal Products" and "Interactions with other Medicinal Products and other Forms of Interaction" provide recommendations on risk management approach **Other risk minimization measures beyond the Product Information:** None **Medicine's Legal Status** Pralsetinib is a prescription only medicine

CDS=core data sheet

11.2 ADDITIONAL RISK-MINIMIZATION MEASURES

Routine risk-minimization activities as described in Section 11.1 are sufficient to manage the safety concerns of the medicinal product.

11.3 SUMMARY OF RISK-MINIMIZATION MEASURES

Table 22 Summary Table of Pharmacovigilance Activities and Risk Minimization Activities by Safety Concern

Safety concern	Risk minimization measures	Pharmacovigilance activities
Pneumonitis	**Routine risk minimization measures:** Sections 2.2 and 2.4 of the CDS "Interstitial Lung Disease/Pneumonitis" provide recommendations on risk	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs.

	management approach. **Additional risk minimization measures:** None	**Additional pharmacovigilance activities:** Studies BO41932, BO42864, CO42865
Hypertension	**Routine risk minimization measures:** Sections 2.2 and 2.4 of the CDS "Hypertension" provide recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO41932, BO42864, CO42865
Hemorrhage	**Routine risk minimization measures:** Section 2.2 of the CDS "Hemorrhagic Events" provides recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO41932, BO42864, CO42865
Hepatotoxicity	**Routine risk minimization measures:** Sections 2.2 and 2.4 of the CDS "Hepatic Transaminase Elevations" provide recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO41932, BO42864, CO42865
Embryo-fetal Toxicity	**Routine risk minimization measures:** Sections 2.4 and 2.5.1 of the CDS "Embryo-fetal Toxicity" and "Females and Males of Reproductive	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs.

	Potential" provide recommendations on risk management approach. **Additional risk minimization measures:** None	**Additional pharmacovigilance activities:** None
Tumor Lysis Syndrome	**Routine risk minimization measures:** Section 2.2 of the CDS "Other Adverse Reactions" provides recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO41932, BO42864, CO42865
Severe Infection	**Routine risk minimization measures:** Section 2.2 of the CDS "Other Adverse Reactions" provides recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO42864, CO42865
Physeal Dysplasia	**Routine risk minimization measures:** Section 2.2 of the CDS "Other Adverse Reactions" provides recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO42864, CO42865
Use in Patients with Severe Hepatic impairment	**Routine risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in

	Additional risk minimization measures: None	PSURs/PBRERs. **Additional pharmacovigilance activities:** Study planned Q1/Q2 2021 (protocol number TBD)
Use in Children	**Routine risk minimization measures:** None **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Studies BO41932, CO42865
Drug-Drug Interaction	**Routine risk minimization measures:** Sections 2.2 and 2.8 of the CDS "Interactions with other Medicinal Products" and "Interactions with other Medicinal Products and other Forms of Interaction" provide recommendations on risk management approach. **Additional risk minimization measures:** None	**Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:** Presentation of cumulative data in PSURs/PBRERs. **Additional pharmacovigilance activities:** Study planned Q1/Q2 2021 (protocol number TBD)